RECENT NEWS

AI Pathology firm Aiforia has announced a commercial agreement with PathAI - the developer of the AISight Dx Image Management System - for Aiforia's AI solutions to be made available to laboratories through the AISight Marketplace.

Lab Innovations, the UK’s largest annual trade show for laboratory professionals and their organisations, has released its show conference programme for 2026, featuring speakers from academic to media backgrounds.

Newly published research uncovers how bacteria fight infection by bacteriophages (phages), opening the door to better virus-based antibiotics.

The Royal College of Pathologists (RCPath) is once again delivering a busy programme for National Pathology Week and International Pathology Day, taking place during November.

The Government has confirmed it will accept all 44 recommendations made by the National Commission into the Regulation of AI in Healthcare. Alongside the response, the MHRA is opening the call for applications for the third phase of AI Airlock, its regulatory sandbox for AI-enabled medical devices.

People who recovered from COVID-19 infection or were vaccinated against SARS-CoV-2 are more likely to have immunity to other closely related bat coronaviruses that could have the potential to threaten future human health.

Pregnant women are currently being recruited to a world-first clinical trial testing a new group B streptococcal vaccine in UK hospitals, which could prevent infant deaths and stillbirths from a life-threatening bacterial infection.

Evident has completed the acquisition of CrestOptics SpA, a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy.

New England Biolabs (NEB) UK and the Microbiology Society have announced a new partnership to widen access to microbiology for under-represented communities.

Thousands more people in Northern Ireland will be invited for potentially life-saving bowel cancer screening after Health Minister Robbie Butler announced a major expansion of the regional screening programme.

PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.

The UK government has launched The Dementia Challenge to accelerate the adoption of innovative technologies and practices that will diagnose and predict how the disease will progress, backed by £80 million of funding.

SYNLAB UK and Ireland officially launched its newest NHS pathology service on 1 October, SYNLAB Essex.

Scientists from UKHSA, the University of Oxford and a collaboration of academic institutions have used bacterial genome sequencing to understand why the meningococcal disease outbreak in Kent in Spring 2026 was so severe.

The NHS has launched a world-first trial of a rapid genomic test for the diagnosis of brain tumours. Available across specialist centres in England, it will mean patients receive a definitive brain tumour diagnosis in days rather than weeks.

An academic and industrial partnership has investigated the antimicrobial activity of two types of disinfectant, finding they are more effective when used together.

The latest annual review of the joint NHS Blood and Transplant (NHSBT) and UK Health Security Agency (UKHSA) Epidemiology Unit has been published by NHSBT.

Revvity has launched its new GSP T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programmes that identify children at risk of developing type 1 diabetes before symptoms appear.

OGT, a global provider of genomic research and diagnostic solutions has unveiled next-generation sequencing (NGS) automation capabilities across its SureSeq NGS portfolio, compatible with the Hamilton NGS STAR Line.

R-Biopharm Rhône is about to celebrate 40 years of innovation, manufacture and export achievement after beginning its journey into the commercial world as a university spin-out.